Li et al. found that FXR agonist obeticholic acid (OCA) inhibits the development and invasion of CRC by attenuating the EMT induced by Wnt/β-catenin and suppressing the activity of the Jak2/Stat3 pathway in human colon cancer cells [117]. This evidence concerns the gene STAT3 and colorectal carcinoma.